{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:35:08Z","timestamp":1791412508762,"version":"4.3.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,1,2]],"date-time":"2016-01-02T00:00:00Z","timestamp":1451692800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s10620-015-4012-2","type":"journal-article","created":{"date-parts":[[2016,1,2]],"date-time":"2016-01-02T05:27:23Z","timestamp":1451712443000},"page":"1721-1727","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":220,"title":["Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation"],"prefix":"10.1007","volume":"61","author":[{"given":"N. M.","family":"Intagliata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z. H.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Maitland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. L.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. K.","family":"Argo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. G.","family":"Northup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. H.","family":"Caldwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,2]]},"reference":[{"key":"4012_CR1","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.cgh.2013.02.026","volume":"11","author":"PG Northup","year":"2013","unstructured":"Northup PG, Caldwell SH. Coagulation in liver disease: a guide for the clinician. Clin Gastroenterol Hepatol. 2013;11:1064\u20131074.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4012_CR2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1056\/NEJMra1011170","volume":"365","author":"A Tripodi","year":"2011","unstructured":"Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365:147\u2013156.","journal-title":"N Engl J Med"},{"key":"4012_CR3","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/jth.12805","volume":"13","author":"KJ Ng","year":"2015","unstructured":"Ng KJ, Lee YK, Huang MY, Hsu CY, Su YC. Risks of venous thromboembolism in patients with liver cirrhosis: a nationwide cohort study in Taiwan. J Thromb Haemost. 2015;13:206\u2013213.","journal-title":"J Thromb Haemost"},{"key":"4012_CR4","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/j.1572-0241.2006.00588.x","volume":"101","author":"PG Northup","year":"2006","unstructured":"Northup PG, McMahon MM, Ruhl AP, et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol. 2006;101:1524\u20131528; quiz 1680.","journal-title":"Am J Gastroenterol"},{"key":"4012_CR5","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/ajg.2008.34","volume":"104","author":"KK Sogaard","year":"2009","unstructured":"Sogaard KK, Horvath-Puho E, Gronbaek H, Jepsen P, Vilstrup H, Sorensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case\u2013control study. Am J Gastroenterol. 2009;104:96\u2013101.","journal-title":"Am J Gastroenterol"},{"key":"4012_CR6","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/hep.27783","volume":"62","author":"F Cerini","year":"2015","unstructured":"Cerini F, Gonzalez JM, Torres F, et al. Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. Hepatology. 2015;62:575\u2013583.","journal-title":"Hepatology"},{"key":"4012_CR7","doi-asserted-by":"crossref","unstructured":"Senzolo M, Ferronato C, Burra P, Sartori MT. Anticoagulation for portal vein thrombosis in cirrhotic patients should be always considered. Intern Emerg Med. 2009;4:161\u2013162; author reply 163\u2013164.","DOI":"10.1007\/s11739-008-0219-y"},{"key":"4012_CR8","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/MCG.0b013e3181b3ab44","volume":"44","author":"L Amitrano","year":"2010","unstructured":"Amitrano L, Guardascione MA, Menchise A, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol. 2010;44:448\u2013451.","journal-title":"J Clin Gastroenterol"},{"key":"4012_CR9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1478-3231.2010.02358.x","volume":"31","author":"LP Bechmann","year":"2011","unstructured":"Bechmann LP, Sichau M, Wichert M, Gerken G, Kroger K, Hilgard P. Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int. 2011;31:75\u201382.","journal-title":"Liver Int"},{"key":"4012_CR10","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.cgh.2012.01.012","volume":"10","author":"MG Delgado","year":"2012","unstructured":"Delgado MG, Seijo S, Yepes I, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol. 2012;10:776\u2013783.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4012_CR11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/liv.12211","volume":"34","author":"NM Intagliata","year":"2014","unstructured":"Intagliata NM, Henry ZH, Shah N, Lisman T, Caldwell SH, Northup PG. Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding. Liver Int. 2014;34:26\u201332.","journal-title":"Liver Int"},{"key":"4012_CR12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.26998","volume":"60","author":"M Martinez","year":"2014","unstructured":"Martinez M, Tandra A, Vuppalanchi R. Treatment of acute portal vein thrombosis by nontraditional anticoagulation. Hepatology. 2014;60:425\u2013426.","journal-title":"Hepatology"},{"key":"4012_CR13","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/hep.27225","volume":"61","author":"NM Intagliata","year":"2015","unstructured":"Intagliata NM, Maitland H, Northup PG, Caldwell SH. Treating thrombosis in cirrhosis patients with new oral agents: ready or not? Hepatology. 2015;61:738\u2013739.","journal-title":"Hepatology"},{"key":"4012_CR14","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jhep.2010.03.031","volume":"53","author":"A Tripodi","year":"2010","unstructured":"Tripodi A, Primignani M, Chantarangkul V, Mannucci PM. Pro-coagulant imbalance in patients with chronic liver disease. J Hepatol. 2010;53:586\u2013587.","journal-title":"J Hepatol"},{"key":"4012_CR15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40262-013-0034-0","volume":"52","author":"J Graff","year":"2013","unstructured":"Graff J, Harder S. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clin Pharmacokinet. 2013;52:243\u2013254.","journal-title":"Clin Pharmacokinet"},{"key":"4012_CR16","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1177\/1060028015591846","volume":"49","author":"AM Morrill","year":"2015","unstructured":"Morrill AM, Ge D, Willett KC. Dosing of target-specific oral anticoagulants in special populations. Ann Pharmacother. 2015;49:1031\u20131045.","journal-title":"Ann Pharmacother"},{"key":"4012_CR17","doi-asserted-by":"crossref","first-page":"e88390","DOI":"10.1371\/journal.pone.0088390","volume":"9","author":"W Potze","year":"2014","unstructured":"Potze W, Arshad F, Adelmeijer J, et al. Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis. PLoS ONE. 2014;9:e88390.","journal-title":"PLoS ONE"},{"key":"4012_CR18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bcp.12054","volume":"76","author":"D Kubitza","year":"2013","unstructured":"Kubitza D, Roth A, Becka M, et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2013;76:89\u201398.","journal-title":"Br J Clin Pharmacol"},{"key":"4012_CR19","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/jcph.550","volume":"55","author":"J Mendell","year":"2015","unstructured":"Mendell J, Johnson L, Chen S. An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 2015;55:1395\u20131405.","journal-title":"J Clin Pharmacol"},{"key":"4012_CR20","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1177\/0091270008324179","volume":"48","author":"J Stangier","year":"2008","unstructured":"Stangier J, Stahle H, Rathgen K, Roth W, Shakeri-Nejad K. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol. 2008;48:1411\u20131419.","journal-title":"J Clin Pharmacol"},{"key":"4012_CR21","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692\u2013694.","journal-title":"J Thromb Haemost"},{"key":"4012_CR22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2013.03.036","volume":"59","author":"A Tripodi","year":"2013","unstructured":"Tripodi A, Primignani M, Lemma L, Chantarangkul V, Mannucci PM. Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. J Hepatol. 2013;59:265\u2013270.","journal-title":"J Hepatol"},{"key":"4012_CR23","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","volume":"143","author":"E Villa","year":"2012","unstructured":"Villa E, Camma C, Marietta M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143:1253\u20131260.","journal-title":"Gastroenterology"},{"key":"4012_CR24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.thromres.2014.11.008","volume":"135","author":"MH Prins","year":"2015","unstructured":"Prins MH, Bamber L, Cano SJ, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thromb Res. 2015;135:281\u2013288.","journal-title":"Thromb Res"},{"key":"4012_CR25","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood-2014-07-590323","volume":"124","author":"C Chai-Adisaksopha","year":"2014","unstructured":"Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood. 2014;124:2450\u20132458.","journal-title":"Blood"},{"key":"4012_CR26","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799\u2013808.","journal-title":"N Engl J Med"},{"key":"4012_CR27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1160\/TH13-05-0431","volume":"111","author":"G Dickneite","year":"2014","unstructured":"Dickneite G, Hoffman M. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? Thromb Haemost. 2014;111:189\u2013198.","journal-title":"Thromb Haemost"},{"key":"4012_CR28","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","volume":"373","author":"CV Pollack Jr","year":"2015","unstructured":"Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511\u2013520.","journal-title":"N Engl J Med"},{"key":"4012_CR29","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","volume":"371","author":"DM Siegal","year":"2015","unstructured":"Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;371:2413\u20132424.","journal-title":"N Engl J Med"},{"key":"4012_CR30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2014.03.026","volume":"61","author":"S Russmann","year":"2014","unstructured":"Russmann S, Niedrig DF, Budmiger M, et al. Rivaroxaban postmarketing risk of liver injury. J Hepatol. 2014;61:293\u2013300.","journal-title":"J Hepatol"},{"key":"4012_CR31","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/heartjnl-2013-305288","volume":"100","author":"D Caldeira","year":"2014","unstructured":"Caldeira D, Barra M, Santos AT, et al. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart. 2014;100:550\u2013556.","journal-title":"Heart"},{"key":"4012_CR32","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/bjh.12593","volume":"163","author":"W Potze","year":"2013","unstructured":"Potze W, Arshad F, Adelmeijer J, et al. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis. Br J Haematol. 2013;163:666\u2013673.","journal-title":"Br J Haematol"},{"key":"4012_CR33","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/hep.27350","volume":"61","author":"W Potze","year":"2015","unstructured":"Potze W, Adelmeijer J, Lisman T. Decreased in vitro anticoagulant potency of Rivaroxaban and Apixaban in plasma from patients with cirrhosis. Hepatology. 2015;61:1435\u20131436.","journal-title":"Hepatology"},{"key":"4012_CR34","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jhep.2006.08.023","volume":"46","author":"W Abe","year":"2007","unstructured":"Abe W, Ikejima K, Lang T, et al. Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat. J Hepatol. 2007;46:286\u2013294.","journal-title":"J Hepatol"},{"key":"4012_CR35","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1124\/jpet.114.218545","volume":"351","author":"AK Kopec","year":"2014","unstructured":"Kopec AK, Joshi N, Towery KL, et al. Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice. J Pharmacol Exp Ther. 2014;351:288\u2013297.","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-015-4012-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-015-4012-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-015-4012-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T16:43:40Z","timestamp":1654015420000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-015-4012-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,2]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["4012"],"URL":"https:\/\/doi.org\/10.1007\/s10620-015-4012-2","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,2]]}}}